Medical/Pharmaceuticals

Clicklinks | 14-Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery

SHANGHAI, April 15, 2026 /PRNewswire/ --  01 Introduction In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success or failure. However, traditional molec...

2026-04-15 22:00 4636

Datasea Inc. (NASDAQ: DTSS) Advances International Commercialization of Acoustic + AI Wellness Care Robots and Prepares U.S. Launch of Acoustic Disinfection Products

Based on preliminary internal assessments, these initiatives may contribute approximately $10 million in incremental revenue in the next fiscal year, subject to execution and market conditions BEIJING, April 15, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a tec...

2026-04-15 21:50 8505

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originat...

2026-04-15 20:00 5543

Osara Health Publishes New Peer-Reviewed Study Demonstrating Clinically Meaningful Improvements in Physical and Mental Health for People With Cancer

Findings published in JMIR Cancer show measurable health gains for Osara Health participants, adding to a growing evidence base including a 25:1 independently validated return on investment. NEW YORK, April 15, 2026 /PRNewswire/ -- Osara Health

2026-04-15 20:00 3132

Taiho Ventures, LLC Celebrates 10th Anniversary

TOKYO and MENLO PARK, Calif., April 15, 2026 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Taiho Ventures, LLC (TVL), a strategic corporate venture capital (CVC) arm of Taiho Pharmaceutical, announced on April 15 that TVL has reached its 10th anniversary since its est...

2026-04-15 14:00 4515

Reach Surgical Receives CE Mark Approval for iREACH IRIS, First Powered Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation

-iREACH IRIS provides real-time, location-specific insight into tissue behaviour along the staple line SINGAPORE, April 15, 2026 /PRNewswire/ -- Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for iREACH IRIS, a next-generation powered stapling p...

2026-04-15 11:30 2210

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

* Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients * Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics...

2026-04-15 10:39 2969

SinoUnited Health Attracts International Patients as China Emerges as Global Medical Tourism Destination

SHANGHAI, April 14, 2026 /PRNewswire/ -- From CAR-T Cell Therapy and cardiac interventions to health checkups and dental care, China's medical capabilities have increasingly drawn international patients in recent years—underscoring the country's rising influence in the global healthcare landscape...

2026-04-15 09:17 3346

SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial

SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Bio...

2026-04-15 08:00 4610

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix's pivotal IPAX BrIGHT trial[1], marking the first radiopharmaceutical...

2026-04-15 06:50 4310

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix ...

2026-04-15 06:35 5684

Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut

A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-...

2026-04-15 06:00 3585

Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results

SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". ...

2026-04-14 22:00 4583

TCI Biotech Returns to Vitafoods Europe 2026 with Five Provocations for the Nutraceutical Industry and a Glimpse of the Future

BARCELONA, Spain, April 14, 2026 /PRNewswire/ -- TCI Biotech, the global CDMO+ leader in health and wellness innovation, will return to Vitafoods Europe 2026 at booth 3F40, Fira Barcelona Gran Via, armed with five bold challenges to the industry's most stubborn pain points. Building on 46 years ...

2026-04-14 22:00 3764

Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026

Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...

2026-04-14 21:08 3910

NYSE Content Update: OpenLoop Health Debuts At-Home Sleep Apnea Test with 98% Accuracy

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 14, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begi...

2026-04-14 21:03 6585

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...

2026-04-14 21:02 3993

Telix Refinances Convertible Bonds

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc....

2026-04-14 16:32 6070

Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development

TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...

2026-04-14 15:11 4411

triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy

All-in-one approach integrates chromosomal analysis, single-gene disorder screening, and maternal carrier screening from a single blood draw.  TAIPEI, April 14, 2026 /PRNewswire/ -- At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG) 2026 Annual M...

2026-04-14 11:30 4221
1 ... 11121314151617 ... 650